TRx is a clinical-stage drug development company leveraging a proprietary targeted oral drug delivery platform across a growing portfolio of partnered and wholly-owned biopharma products. TRx is utilising natural human biology to access a novel drug uptake channel, so providing an alternative and unexploited mechanism for oral drug absorption compared to both traditional and state-of-the-art oral formulation technologies. TRx’s technology delivers numerous benefits that can be harnessed simultaneously, including significantly increased bioavailability alongside various pharmacodynamic enhancements, enabling targeted oral drug delivery to specific organs, tissues and cells in cancer, CNS, respiratory diseases and diseases of the immune system. TRx’s targeted approach can also remove or reduce the impact of adverse effects, offering scope for enhanced gastric, cardiac and hepatic-related off-target effects. Collectively, these benefits lead to fundamental changes in drug biodistribution and performance, which can be rapidly accessed and validated in pre-clinical and clinical settings. TRx operates a flexible and collaborative technology partnering and licensing model as it seeks to integrate its technology into a range of future new therapies. For more information contact TRx Biosciences directly.

Infirst Healthcare was established to commercialise the lipid delivery platform developed within the SEEK Group. This platform uses GRAS and/or pharmaceutical approved ingredients, is inexpensive to manufacture and is patent protected. This technology can be applied to a wide range of lipophilic molecules.  The lipid allows for increased bioavailability for lipophilic molecules and more targeted distribution to areas of interest in the body. The first product commercialised out of this platform is an enhanced version of ibuprofen called Flarin, which has now been spun out into a separate company. Details can be found on the Flarin website.

ConserV’s mission is to develop safe and effective vaccines which offer broad protection against infections from viruses that mutate frequently. ConserV specialises in the identification of antigens consisting of conserved regions of viral proteins containing a high number of reactive T cell epitopes with extensive MHC coverage. ConserV is developing two clinical stage assets on behalf of Imutex Limited - its joint venture with hvivo plc - a broad-spectrum influenza vaccine and a vaccine against mosquito saliva (which aims to protect against infection from all mosquito-borne diseases). ConserV also has a further pipeline of six pre-clinical / early-stage clinical vaccines in development. To explore ConserV's pipeline, please visit the ConserV website.